Quantcast

Latest Exenatide Stories

2014-09-19 08:25:27

-- Patients treated with ITCA 650 for 6 months showed an average HbA1c reduction of -3.2% at the time of the interim analysis; patients at baseline had HbA1c greater than or equal to 10% to 12%. VIENNA, Sept. 19, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the presentation of positive interim clinical data for its lead candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in type 2 diabetes patients with high baseline HbA1c levels at the 50(th) Annual Meeting...

2014-09-18 20:22:43

- Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Trulicity(TM) (dulaglutide), approved today by the U.S. Food and Drug Administration, is the latest Eli Lilly and Company (NYSE: LLY) treatment option for adults with type 2 diabetes. Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2...

2014-09-17 08:29:46

- Data indicate 58% non-adherence to second-line treatments in T2D patients, significantly higher than patients report and prescribers perceive VIENNA, Sept. 17, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the presentation of compelling, quantitative data from a study of the cost and predictability of non-adherence in type 2 diabetes therapies at the 50(th) Annual Meeting of the European Association for the Study of Diabetes (EASD). In a poster session today, Christian...

2014-09-11 23:01:20

The Firm is evaluating Byetta lawsuits on behalf of individuals who developed pancreatitis, pancreatic cancer or thyroid cancer allegedly due to their use of Byetta or other incretin mimetic Type 2 diabetes drug. New York (PRWEB) September 11, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and legal claims involving other incretin mimetic Type 2 diabetes drugs, including Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District...

2014-09-11 16:28:19

- Oral presentation 9/19: interim Phase 3 results for ITCA 650 among patients with high baseline (HBL) HbA1c levels between 10-12% showed dramatic HbA1c reductions, even in patients with high HbA1c despite multi-drug therapy BOSTON, Sept. 11, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced its participation in the 50(th) Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15 -19. Intarcia's lead product...

2014-08-30 23:02:07

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of the medication. New York, New York (PRWEB) August 30, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in U.S. courts, Bernstein Liebhard LLP reports. According to a statement issued by AstraZeneca PLC on July 31, 2014, Byetta and Bydureon (an extended-release...

2014-08-15 23:00:59

The Firm is actively investigating Januvia and Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and other serious injuries after taking either of the diabetes treatments. New York, NY (PRWEB) August 15, 2014 Healthcare regulators in British Columbia have stopped patient coverage of a diabetes drug now involved in hundreds of Byetta lawsuits (http://www.byettalawsuit.com/) as well as several other medications, Bernstein Liebhard LLP reports....

diabetes drug metformin
2014-08-11 04:19:36

April Flowers for redOrbit.com - Your Universe Online A large-scale study from Cardiff University, involving over 180,000 people, reveals that people with Type 2 diabetes can live longer than those without the condition, thanks to a widely prescribed blood glucose control medication. The findings, published in Diabetes, Obesity and Metabolism, suggest that metformin — commonly used to control glucose levels in the body and known for exhibiting anticancer properties — could offer...

2014-08-10 23:01:12

The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid cancer. New York, New York (PRWEB) August 10, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and legal claims involving other incretin mimetic Type 2 diabetes drugs, such as Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District...

2014-08-05 08:35:45

- Zalani joins Intarcia to drive the strategic and operational direction of Intarcia's Global Regulatory and Quality efforts with health authorities, partners and external stakeholders - BOSTON, Aug. 5, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today officially announced the appointment of Sunita Zalani, Ph.D., as Vice President and Global Head of Regulatory Affairs and Quality. In her new capacity, Dr. Zalani serves on the Leadership Team and reports directly to Chairman,...


Latest Exenatide Reference Libraries

36_67c6fec75293d7e1e91a0c52aa692cf7
2005-06-22 14:17:05

The Gila monster (Heloderma suspectum) is one of the two known species of venomous lizards. This lizard lives in the deserts of the southwestern USA and northwestern Mexico. It is a heavy, slow moving lizard and can measure up to 2 feet (60 cm) in length. Its skin has the appearance of beads in the colors black, pink, orange, and yellow, laid down in intricate patterns across the animal's body. Unlike a snake, the Gila monster envenomates its victim through grooves in the teeth of its...

More Articles (1 articles) »
Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related